Next Article in Journal
Apparent Total Tract Digestibility of Energy, Concentrations of Digestible Energy and Metabolizable Energy, and Nitrogen Balance in Growing Pigs Fed Bakery Meal and Biscuit Meal with Multi-Enzyme
Next Article in Special Issue
Effects on Performance, Immunological Response and Short-Chain Fatty Acid Profile in Feces of Nursery Piglets Fed with Organic Acids and Yeast Wall
Previous Article in Journal
YOLOv8A-SD: A Segmentation-Detection Algorithm for Overlooking Scenes in Pig Farms
Previous Article in Special Issue
Dietary Glyceryl Polyethylene Glycol Ricinoleate as an Additive to Improve Intestinal Health in Post-Weaning Piglets
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Fucoidan Alleviates Porcine Epidemic Diarrhea Virus-Induced Intestinal Damage in Piglets by Enhancing Antioxidant Capacity and Modulating Arginine Metabolism

by
Qian Zhang
,
Maojing Wang
,
Zhonghua Li
,
Di Zhao
,
Yongqing Hou
and
Tao Wu
*
Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan 430023, China
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Animals 2025, 15(7), 1001; https://doi.org/10.3390/ani15071001
Submission received: 26 February 2025 / Revised: 21 March 2025 / Accepted: 28 March 2025 / Published: 30 March 2025
(This article belongs to the Special Issue Gastrointestinal Tract Health in Pigs—2nd Edition)

Simple Summary

This study aimed to investigate the protective effects of FUC on PEDV-induced intestinal injury in piglets and to explore its underlying mechanisms. The results show that FUC supplementation could alleviate the disruption of intestinal morphology and function caused by PEDV infection. FUC enhanced the antioxidant capacity of the piglets. Transcriptional profiling combined with quantitative analysis revealed that FUC regulates immune responses, substance transport, and arginine metabolism. Notably, FUC downregulated arginase 1 expression, suggesting a redirection of arginine toward nitric oxide synthesis, thereby placing the host in an antiviral state. These findings highlight the potential application of FUC as a natural agent for mitigating PEDV-induced intestinal damage and improving gut health.

Abstract

Porcine epidemic diarrhea virus (PEDV) causes severe intestinal damage, posing significant threats to the swine industry. Fucoidan (FUC), a biologically active compound, exhibits antiviral activity against multiple viruses. This study aimed to investigate the protective effects of FUC on PEDV-induced intestinal injury in piglets and explore its underlying mechanisms. A total of 28 healthy crossbred piglets were randomly allocated into four experimental groups using a 2 × 2 factorial design: (1) a control group, (2) an FUC group, (3) a PEDV group, and (4) an FUC+PEDV group. From day 4 to day 10, the piglets in the FUC and FUC+PEDV groups were orally administered fucoidan at a dosage of 20 mg/kg body weight (BW) each day. On day 8, the piglets in the PEDV and FUC+PEDV groups were orally administered PEDV at a dose of 3 × 105.5 TCID50. The results show that FUC supplementation significantly decreased plasma DAO activity (p < 0.05) and increased the villus height, villus area, as well as the villus height/crypt depth (p < 0.05) in the intestine when compared to the PEDV-infected piglets. This indicates that FUC could alleviate the disruption of intestinal morphology and function caused by PEDV infection. FUC enhanced the antioxidant capacity of the piglets by increasing SOD and GSH-Px activity. Transcriptional profiling combined with quantitative analysis revealed that FUC regulates immune responses, substance transport, and arginine metabolism. Notably, FUC downregulated arginase 1 expression, which may redirect arginine toward nitric oxide synthesis, thereby establishing an antiviral state in the host. These findings highlight the potential application of FUC as a natural agent for mitigating PEDV-induced intestinal damage and improving gut health. Additionally, monitoring the health status of piglets is necessary when FUC is applied in practical applications.

1. Introduction

The animal intestinal tract plays a pivotal role in nutrient absorption and barrier function, which are essential for maintaining adequate nutrition. Beyond its role in nutrient regulation, the intestinal tract also serves as a critical barrier, preventing pathogen invasion and preserving intestinal integrity [1]. In practice, numerous factors can contribute to intestinal damage in piglets, among which the porcine epidemic diarrhea virus (PEDV) is a prominent causative agent. PEDV causes porcine epidemic diarrhea (PED), which is an acute, highly contagious enteric disease. This virus exhibits high pathogenicity and can infect pigs of all ages and breeds, with piglets being the most severely affected, often presenting with pronounced clinical symptoms, including vomiting, diarrhea, and lethargy [2]. PEDV primarily targets intestinal epithelial cells, causing rapid cell lysis, necrosis, and villous atrophy [3]. Additionally, the enzymatic activity and content of damaged cells are significantly diminished, leading to a compromise of the gut’s nutrient absorption capacity [4]. Despite widespread vaccination, the infection rate of PEDV has risen significantly due to the highly mutated rates of amino acids within the neutralizing epitopes of the spike gene [5,6]. This poses a substantial threat to the swine industry nationwide.
Polysaccharides derived from animals, plants, and microorganisms are natural products known for their ability to regulate various physiological functions. They are characterized by their safety, low toxicity, and minimal side effects [7]. Fucoidan (FUC), a sulfated polysaccharide primarily composed of L-fucose and sulfate groups, also contains trace amounts of xylose, mannose, arabinose, galactose, and glucuronic acid [8]. FUC is predominantly found in the cell walls and intercellular spaces of brown algae, such as kelp and wakame [9]. FUC does not cause significant toxicity within reasonable dosage ranges. Recent studies have demonstrated that FUC exhibits a wide range of biological activities, including anticoagulant, antibacterial, antiviral, antitumor, and immunomodulatory effects [10,11]. FUC modulates the intestinal mucosal barrier, thereby stabilizing the microecological environment and mitigating inflammatory responses [12]. FUC promotes intestinal health by regulating gut microbiota, repairing the intestinal mucosa, enhancing digestive enzyme activity, and increasing the number of goblet cells [13]. Moreover, it attenuates pro-inflammatory responses, such as IL-6 and TNF-α, in porcine intestinal epithelial cells stimulated by E. coli through the NF-κB signaling pathway, while also reducing bacterial adhesion and invasion [14]. Numerous studies have demonstrated that both naturally extracted and synthetic sulfated polysaccharides exhibit inhibitory activity against a variety of DNA and RNA viruses in vitro and in vivo [15]. Research indicates that FUC can inhibit the entry of SARS-CoV-2 into host cells by binding to the spike glycoprotein [16,17]. Additionally, FUC has been shown to effectively block influenza A virus infection in vitro, with low toxicity and minimal propensity for inducing viral resistance [18]. Although FUC has been shown to protect the intestinal tract and exhibit antiviral effects, there is a lack of research on its ability to defend against viral infections in the intestines of pigs and/or other animal species. Therefore, we conducted this study to evaluate the effects of FUC on intestinal injury induced by PEDV in piglets.

2. Materials and Methods

2.1. Experimental Materials and Diets

Fucoidan (purity > 85%) was purchased from Shanghai Yuanye Bio-Technology Co., Ltd. (Shanghai, China). A PEDV strain (Yunnan Province strain 8) was provided by the Hubei Key Laboratory of Animal Nutrition and Feed Science at Wuhan Polytechnic University, Wuhan, China.

2.2. Animals and Experiment Design

A total of 28 healthy 7-day-old crossbred piglets (initial body weight: 2.49 ± 0.38 kg) were selected for this experiment. All the piglets were negative for PEDV by the experiment, which was confirmed by real-time PCR. They were randomly allocated into four experimental groups using a 2 × 2 factorial design: (1) a control group, (2) an FUC group, (3) a PEDV group, and (4) an FUC+PEDV group. The experimental period lasted for 11 days, with the first three days allocated for adaptation. From day 4 to day 10, piglets in the FUC and FUC+PEDV groups were orally administered fucoidan (dissolved in milk) at a dosage of 20 mg/kg body weight (BW) each day. The same volume of milk was provided to the piglets in the control and PEDV groups. On day 8, piglets in the PEDV and FUC+PEDV groups were orally administered PEDV at a dose of 3 × 105.5 TCID50. This dosage was determined according to our previous study, with slight adjustments [19]. Piglets in the control and FUC groups received an equivalent DMEM solution. Fasting was initiated at 22:00 on day 10, with water and feed withdrawn for 8 h. At 06:00 on day 11, fasting body weights were recorded, followed by sequential oral administration of d-xylose (0.1 g/kg body weight) via gavage. Peripheral blood samples were collected from the jugular vein using EDTA-coated vacutainers. Terminal procedures commenced with intramuscular anesthesia (sodium pentobarbital, 50 mg/kg BW). Tissue samples were immediately snap-frozen in liquid nitrogen and stored at −80 °C for subsequent analysis.
Piglets were weighed on an empty stomach each morning on days 0, 4, 8, and 11, with weights recorded to calculate the average daily gain (ADG). Throughout the experimental period, diarrhea and morbidity were observed both before and after each feeding session, and fecal morphology was assessed using a standardized scoring system: normal, dry feces were scored as 0; feces in a pasty state were scored as 1; feces in a semi-liquid state were scored as 2; and feces in a liquid state were scored as 3.

2.3. Biochemical Measurements in Plasma

Blood samples were gently inverted several times to ensure thorough mixing of the blood with the anticoagulant and to prevent coagulation. Plasma and serum were subsequently separated by centrifugation. And the fresh plasma samples were immediately used for biochemical parameter analysis with a Hitachi 7100 Automatic Biochemical Analyzer (Hitachi, Tokyo, Japan).

2.4. Determination of D-Xylose and Diamine Oxidase Activity in Plasma

Colorimetric methods were employed to measure d-xylose content and diamine oxidase (DAO) activity in plasma using kits obtained from the Nanjing Jiancheng Bioengineering Institute (d-xylose: catalog number A035-1-1; DAO: catalog number A088-1-1). All assays were conducted in accordance with the manufacturer’s instructions.

2.5. Antioxidant Capacity in Serum and Intestinal Mucosa

The antioxidant enzymes and their associated products were analyzed using serum and intestinal mucosa samples from piglets. The activities and concentrations of glutathione peroxidase (GSH-Px), superoxide dismutase, total superoxide dismutase (T-SOD), myeloperoxidase (MPO), malondialdehyde (MDA), and hydrogen peroxide (H2O2) were measured using commercially available reagent kits from the Nanjing Jiancheng Institute of Bioengineering (Nanjing, China).

2.6. Intestinal Histomorphology

Briefly, 1 cm intestinal segments were fixed in 4% paraformaldehyde, dehydrated, and embedded in paraffin. Sections with a thickness of 6 µm were cut, deparaffinized with xylene, and stained with hematoxylin and eosin. Morphometric parameters, including the villus height (VH), crypt depth (CD), villus width (VW), and the ratio of the villus height to crypt depth (VH/CD), were measured using an Olympus BX41 microscope (Tokyo, Japan) and analyzed with the ImageProPlus 6.0 software (Media Cybernetics, Rockville, MD, USA).

2.7. Real-Time PCR

The total RNA was extracted from approximately 100 mg of intestinal tissue using RNAiso Plus (Takara, Dalian, China). RNA concentration was quantified using a NanoDrop® ND-2000 UV-VIS spectrophotometer (Thermo Scientific, Wilmington, DE, USA), and RNA integrity was verified by 1% agarose gel electrophoresis. Complementary DNA (cDNA) was synthesized using the PrimeScript® RT reagent Kit with gDNA Eraser (Takara, Dalian, China). Gene expression levels were analyzed by quantitative real-time PCR (qPCR) using SYBR® Premix Ex Taq™ (Tli RNaseHPlus) (Takara, Dalian, China) on an Applied Biosystems 7500 Fast Real-Time PCR system (Applied Biosystems, Waltham, MA, USA). The ribosomal protein L19 (RPL19) gene served as the internal reference, and relative gene expressions were calculated and statistically analyzed using the 2−ΔΔCt method. Primer sequences for the target genes are provided in Table 1.

2.8. Sequencing and Analysis of the Jejunal Transcriptome

Twelve jejunal samples from three treatment groups were selected for transcriptome analysis. The total RNA was extracted from the tissues using the Trizol reagent, and RNA quality was assessed to ensure purity and integrity. Eukaryotic mRNA was enriched using oligo (dT) magnetic beads and reverse-transcribed into cDNA. Sequencing libraries were constructed and quality-checked using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). High-throughput sequencing was performed on the Illumina Novaseq 6000 platform. Differentially expressed genes (DEGs) were identified with thresholds set at q value < 0.05 and fold change > 1.5. Functional annotation of the DEGs was conducted through Gene Ontology (GO) analysis using the GO database (http://geneontology.org/) (accessed on 23 January 2025) and pathway enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (https://www.kegg.jp/) (accessed on 23 January 2025).

2.9. Statistical Analyses

Statistical analysis was performed using two-way ANOVA (2 × 2 factorial design) through the General Linear Model procedure in SPSS 26.0 (SPSS Inc., Chicago, IL, USA). The model included the main effects of dietary treatment (FUC-supplemented vs. FUC-free) and the challenge status (DMEM vs. PEDV), as well as their interaction term. Post hoc comparisons were conducted using Duncan’s test when significant interactions (p < 0.05) were detected. Data are expressed as means ± pooled standard errors of the mean (SEM), with statistical significance defined at p < 0.05.

3. Results

3.1. Growth Performance

As shown in Table 2, PEDV infection significantly reduced ADG and increased the diarrhea scores of the piglets (p < 0.05). However, FUC supplementation had no significant effect on ADG and diarrhea scores after PEDV infection.

3.2. The mRNA Levels of PEDV Genes in the Jejunum, Ileum, and Colon

The relative expression levels of PEDV M, N, and S mRNA are summarized in Table 3. PEDV infection significantly increased the relative expression of PEDV M, N, and S mRNA, and the supplementation of FUC resulted in a further increase in their expression levels (p < 0.05).

3.3. Plasma Biochemical Parameters

The effects of FUC on blood biochemical parameters in piglets infected with PEDV are shown in Table 4. Compared with the uninfected PEDV piglets, the PEDV-infected piglets had increased UREA concentrations (p < 0.05) and decreased concentrations of lactate dehydrogenase (LDH), total cholesterol (TC), high-density lipoprotein (HDL-C), and direct bilirubin (DB) in plasma (p < 0.05). FUC administration decreased plasma LDH, total bilirubin (TB), HDL-C, and DB (p < 0.05). There were significant interactive effects between PEDV and FUC on plasma TB and DB concentrations (p < 0.05).

3.4. Blood DAO Activity and D-Xylose Concentrations

Data on plasma DAO activity and d-xylose concentrations are shown in Table 5. Compared to the uninfected PEDV piglets, PEDV infection significantly decreased plasma d-xylose concentrations (p < 0.05). There were interactive effects between PEDV and FUC on DAO activity. Following PEDV infection, FUC supplementation significantly decreased plasma DAO activity (p < 0.05) when compared to the PEDV-infected piglets.

3.5. Intestinal Morphology

PEDV infection induced obvious villous atrophy in the small intestine, which improved with FUC supplementation (Figure 1). As shown in Table 6, compared to the uninfected PEDV piglets, the PEDV-infected piglets had a lower villus height, villus area, and villus height/crypt depth ratios in the small intestine and a lower villus width in the duodenum and jejunum. Additionally, these infected piglets showed a lower crypt depth in the jejunum and a higher crypt depth in the colon (p < 0.05). Piglets supplemented with FUC had higher villus height-to-crypt depth ratios in the small intestine and higher villus heights in the duodenum and jejunum (p < 0.05). Notably, there was an interaction between PEDV infection and FUC supplementation on the intestinal villus height, villus area, and villus height/crypt depth ratios. Specifically, the piglets in the FUC+PEDV groups showed a significantly higher villus height and villus area in the duodenum and ileum as well as a higher villus height/crypt depth in the duodenum (p < 0.05) compared to the PEDV groups.

3.6. Intestinal Antioxidant Capacity

The effects of FUC supplementation on the intestinal antioxidant capacity in the PEDV-infected piglets are shown in Table 7. Compared to the control group, FUC supplementation significantly reduced H2O2 levels in the jejunum, ileum, and colon as well as the MDA content in the ileum and MPO activity in the duodenum, jejunum, and colon (p < 0.05). PEDV infection resulted in lower H2O2 concentrations in the plasma, jejunum, and ileum as well as decreased T-SOD activities in plasma and GSH-Px activities in the ileum (p < 0.05). Additionally, MDA concentrations were elevated in the duodenum and colon (p < 0.05). Interaction effects between PEDV infection and FUC supplementation were observed, with the infected piglets receiving FUC exhibiting lower H2O2 levels in the jejunum, increased SOD activity (p < 0.05), reduced MDA concentrations in the ileum (p < 0.05), and enhanced GSH-Px activity alongside decreased MPO activity in the duodenum (p < 0.05).

3.7. Transcriptome Analysis

A total of 2398 and 928 DEGs were identified in the PEDV vs. control and PEDV+FUC vs. PEDV comparisons, respectively. And the number of overlapped genes between the PEDV vs. control and PEDV+FUC vs. PEDV comparisons was 282 (Figure 2A,B). To elucidate the biological processes associated with PEDV pathogenesis and FUC’s therapeutic effects, GO and KEGG analyses were systematically performed. The DEGs between the control and PEDV groups were predominantly enriched in immune response-associated biological processes, such as “neutrophil chemotaxis”, “chemokine-mediated signaling pathway”, “inflammatory response”, “regulation of neuroinflammatory response”, and “cellular response to type II interferon”, and virus-associated biological processes, such as “negative regulation of viral genome replication” and “response to virus” (Figure 2C). Similar findings were observed in the KEGG pathway analysis (Figure 2E). In addition, “mineral absorption”, “protein digestion and absorption”, “pyrimidine metabolism”, “p53 signaling pathway”, “PI3K-Akt signaling pathway”, and “FoxO signaling pathway” were also enriched for the DEGs between the control and PEDV groups. DEGs between the PEDV and PEDV+FUC groups were mostly enriched in metabolism-associated biological processes, especially lipid metabolism-associated biological processes, such as “linoleic acid metabolic process”, “fatty acid metabolic process”, “steroid metabolic process”, “cholesterol efflux”, and “triglyceride biosynthetic process” (Figure 2D). Substance transport processes, such as “transmembrane transport” and “sodium ion transport”, were also significantly enriched. Similar findings were observed in the KEGG pathway analysis (Figure 2F). Notably, arginine metabolisms, such as “arginine biosynthesis” and “arginine and proline metabolism”, were significantly enriched.

3.8. The Expression of Immune-Associated Genes upon PEDV Infection and FUC Supplementation in the Jejunum of Piglets

During viral infection, both antiviral-related genes and inflammatory cytokines were significantly upregulated (p < 0.05) (Figure 3). A significant interaction effect between PEDV infection and FUC supplementation was observed on mRNA expression levels of ISG15, IFN-β, IL-1β, CXCL2, S100A2, and IL-8 (p < 0.05). FUC supplementation further increased the expression of IFN-β, IL-1β, CXCL2, S100A2, and IL-8 while significantly downregulating ISG15 expression compared to PEDV infection alone.

3.9. The Expression of Transport- and Arginine Metabolism-Associated Genes upon PEDV Infection and FUC Supplementation in the Jejunum of Piglets

During PEDV infection, the mRNA expression levels of aquaporin genes (AQP3 and AQP10); sodium–hydrogen exchangers (NHE2 and NHE3); apolipoproteins (APOA1, APOA4, APOB, and APOC3); TRPV6; KCNJ13; and ASS1 were significantly downregulated (Figure 4), while the mRNA expression levels of ARG1 were significantly upregulated. Notably, with the exception of AQP3, AQP10, and KCNJ13, PEDV infection showed interaction effects with FUC supplementation on the transcriptional regulation of other investigated genes. Specifically, the addition of FUC caused a further reduction in mRNA expression levels of NHE2, TRPV6, APOA1, APOA4, APOB, APOC3, and ASS1 compared to PEDV infection alone, while FUC supplementation counteracts PEDV-induced ARG1 upregulation.

4. Discussion

Gastrointestinal health is a critical factor in animal performance, and plant-derived polysaccharides have emerged as an important source of bioactive compounds with significant pharmacological properties [20], among which FUC is a promising candidate for addressing gastrointestinal disorders, such as inflammatory bowel disease (IBD) [21,22]. In this study, we demonstrated that fucoidan can improve the morphology and structure of the intestine, repair the intestinal barrier, and enhance the antioxidant status in PEDV-infected pigs. Furthermore, transcriptomic analysis was employed to elucidate the regulatory mechanisms underlying these effects. This study highlights the potential of FUC as an effective strategy for PEDV prevention and control and provides a theoretical basis for its application in production practices.
Plasma biochemical indicators reflect an organism’s health status, particularly in terms of metabolism, immune regulation, and cellular function [23]. Key lipids such as TC and HDL-C indicate lipid metabolism efficiency [24]. Chronic infections, including hepatitis C virus and COVID-19, often reduce serum TC and HDL-C levels due to impaired liver function or systemic inflammation [25,26]. Similarly, patients with IBD exhibit lower TC and HDL levels compared to healthy individuals [27]. In this study, PEDV infection in piglets significantly decreased plasma TC and HDL levels. This indicates that PEDV infection may disrupt lipid metabolism, possibly due to systemic inflammation or oxidative stress caused by the virus. The elevated plasma urea levels observed in this study may reflect increased protein catabolism or impaired renal function [28]. However, FUC supplementation did not have any effect on plasma TC, HDL, and urea levels in the PEDV-infected piglets. Notably, FUC supplementation call-backed TB and DB levels, which were increased by PEDV infection in the plasma. This suggests that FUC supplementation may have a protective effect on liver function [29]. Although PEDV mainly targets enteric cells, severe infections can lead to the systemic circulation of viral particles, potentially infecting hepatocytes directly. Moreover, the oxidative stress induced by PEDV infection may increase reactive oxygen species production, overwhelming the liver’s antioxidant defenses and causing hepatocyte damage, which impairs liver function. In this study, FUC alleviated oxidative stress in the intestine, which may contribute to reducing hepatic injury and protecting liver function. From this perspective, FUC may play a protective role in mitigating PEDV-induced systemic effects.
This study demonstrates that PEDV infection compromises gut barrier function and small intestinal absorption in piglets, as evidenced by elevated plasma DAO activity and reduced d-xylose absorption, which aligns with our previous studies [19]. The intestinal dysfunction may have resulted from intestinal epithelial atrophy and desorption. In this study, we found that FUC mitigated the damage caused by PEDV infection. FUC has been shown to enhance small intestinal barrier function and restore cecal flora balance in weaned goat pups and has been demonstrated to activate the PI3K/Akt pathway to promote cell survival and proliferation, thereby facilitating tissue regeneration [12,30]. FUC’s anti-inflammatory, antioxidant, and immunomodulatory functions could also contribute to repairing intestinal damage [10,11]. In addition, FUCs act as prebiotics, selectively promoting the growth of beneficial bacteria, such as Lactobacillus and Bifidobacterium, while inhibiting pathogenic bacteria. A balanced gut microbiota reduces systemic inflammation, enhances nutrient absorption, and supports the repair of intestinal tissues [12]. However, inconsistent results have been reported, as highlighted by Bonnie Homer’s study, which found no significant improvement in intestinal morphology upon FUC supplementation [31,32]. This discrepancy may be attributed to several factors, including variations in the experimental conditions employed and the molecular characteristics of the FUCs. Studies have demonstrated that a low-molecular-weight FUC with a high sulfate content exhibits stronger bioactivity compared to its high-molecular-weight counterparts [33,34]. A low molecular weight allows for better absorption and interaction with cellular receptors, while a high sulfate content enhances bioavailability and pharmacokinetic properties. Overall, FUCs demonstrate repair effects on intestinal injury induced by PEDV infection.
Under normal physiological conditions, the body maintains a redox balance to prevent oxidative damage. However, this equilibrium is disrupted during pathogen invasion, leading to oxidative stress. PEDV infection alters antioxidant enzyme activities and increases peroxidation products in piglets’ blood and intestines, indicating a reduced antioxidant capacity and elevated oxidative stress. In this study, FUC supplementation showed positive effects by enhancing GSH-Px and T-SOD activities while reducing MDA levels. These findings indicate that FUCs alleviate PEDV-induced oxidative stress by improving the antioxidant capacity and protecting intestinal health. Similar findings were observed in other studies. Ryu et al. (2016) found that FUCs upregulate the expression of antioxidant enzymes, such as SOD, at the transcriptional level by activating Nrf2, a master regulator of antioxidant response [35]. In Caco-2 cells, FUC activated the Nrf2/HO-1 pathway to facilitate the antioxidant activities under oxidative stress through elevating the SOD and GSH levels [36]. The authors proposed that FUCs’ negatively charged sulfate groups directly interact with the positively charged regions on these enzymes, thus forming a protective layer around the enzyme and stabilizing their structure. In conclusion, FUC supplementation shows promise in mitigating oxidative stress, highlighting FUC as a potential natural adjunctive therapy for improving the antioxidant capacity during viral infections.
Following a virus infection, the host innate immune system is rapidly activated. Generally, IFNs prime neighboring cells via JAK-STAT pathways to upregulate ISGs, which establish an antiviral state to restrict viral replication and spread [37]. Concurrently, pro-inflammatory cytokines would be induced, recruiting mononuclear inflammatory cells to the infection site and eliminating viral particles [38,39]. However, dysregulated cytokine production would cause serious tissue damage [40]. In this study, PEDV infection significantly upregulated the expression of multiple antiviral and inflammation-related factors in the jejunum, which aligns with our previous findings [19], while FUC supplementation further enhanced the jejunal expression of IFNs and other pro-inflammatory cytokines in PEDV-infected piglets. Notably, ISG15—an interferon-stimulated gene—displayed no concomitant elevation in the PEDV+FUC group despite increased IFN levels. This phenomenon may be attributed to the transient early-phase response characteristics of ISG15, which typically exhibits peak expression during initial viral invasion followed by time-dependent attenuation [41]. Moreover, emerging evidence suggests that ISG15 exerts both anti- and pro-viral effects. The free, extracellular ISG15 has been proposed to implicate in the hyperinflammation seen in severe COVID-19 [42]. Moreover, ISG15 has been shown to regulate cellular processes that include autophagy and metabolism [43]. As for PEDV, we have shown that ISG15 was highly induced upon infection. Its downregulation may contribute to PEDV replication, as we noticed in this study. However, its specific role remains to be investigated. FUC is considered to have anti-inflammatory effects; therefore, the upregulation of inflammatory cytokines observed by FUC supplementation was unexpected. Possible reasons for this are not yet certain and may be related to the dosage of fucoidan, the sampling time, and the condition of the animals. This could be also have been caused by the upregulation of PEDV levels. Furthermore, it is well recognized that mucosal immunity, especially IgA levels, is crucial for managing PEDV infection [39]. Previous studies have shown that FUCs can act as a mucosal adjuvant [44]. Therefore, in subsequent research, it is warranted to examine the influence of FUC on mucosal immune responses during PEDV infection. This will contribute significantly to our understanding of the protective mechanisms by which FUC defends against PEDV in infected piglets. Together, FUC supplementation could modulate immune responses in the PEDV-infected piglets, and attention should be paid to its effects on viral proliferation and inflammatory cytokine expression in practical applications.
The transcriptomic results reveal that the addition of FUC modulates intestinal transport processes. We performed real-time PCR to detect the expression levels of genes related to ion transport, water channels, and lipid transport. A significant downregulation of these genes was observed during PEDV infection. These changes likely exacerbated diarrhea, nutrient malabsorption, and barrier dysfunction, facilitating viral dissemination [45,46,47]. However, FUC supplementation further reduced their expression. This result puzzles us greatly, because FUC showed an improving effect on intestinal function and morphology, which seems to contradict the downregulation of these genes. On the other hand, this may be an adaptive response of the host to the infection, reducing the virus’s utilization of host resources, and FUC enhances this response. Additionally, FUC may compensate for the function of these genes through other pathways, such as activating alternative transport mechanisms or promoting cell proliferation. Moreover, changes in the gut microbiota and their metabolism may indirectly promote intestinal repair. For example, studies have shown that fucose exhibits a beneficial effect on the restoration of the richness and diversity of the gut microbiota community and the beneficial bacterium Muribaculaceae. Concurrently, significant improvements were observed in the structural damage of the intestinal mucosa [48]. Overall, FUC could regulate the expression of genes involved in ion transport, water channels, and lipid transport, which requires careful risk–benefit evaluations in PEDV-infected piglets.
Importantly, we found that FUC supplementation modulated arginine metabolism during PEDV infection. In this study, PEDV infection significantly upregulated the expression of ARG1 while downregulating ASS1 expression. Notably, FUC administration mitigated the PEDV-induced upregulation of ARG1. As ARG1 catalyzes the conversion of arginine to ornithine and urea, its increased activity reduces arginine availability [49]. ASS1 plays a critical role in arginine synthesis within the urea cycle; its downregulation hinders arginine regeneration, exacerbating intracellular arginine depletion. The resulting scarcity of arginine limits the substrate for inducible nitric oxide synthase (iNOS), consequently diminishing nitric oxide (NO) production—a key antiviral molecule [50]. By downregulating ARG1 expression, FUC supplementation may inhibit the metabolic diversion of arginine toward ornithine and urea, redirecting arginine flux toward NO synthesis. This metabolic adjustment could enhance host antiviral defense mechanisms via NO-mediated immune regulation. This is supported by another study which shows that FUC could enhance nitric oxide synthase phosphorylation, thereby affecting NO production [51]. Further studies will be needed to explore the specific mechanisms by which FUC impacts arginine metabolism and to confirm its role in PEDV infection.

5. Conclusions

In summary, the supplementation of FUC demonstrated significant benefits in mitigating PEDV-induced pathologies. Specifically, FUC improved intestinal morphology and function, enhanced the antioxidant capacity of piglets, and modulated immune responses within the intestine. Moreover, FUC intervention regulated transport processes and arginine metabolism in PEDV-infected piglets.
However, to fully realize the therapeutic potential of FUC, future research should prioritize optimizing its structural properties and delivery parameters. Specifically, efforts should be directed toward standardizing FUC formulations based on molecular weights and sulfate contents to ensure consistent efficacy. Investigating dose–response relationships and time-dependent effects is also a critical step toward maximizing FUC’s therapeutic benefits. Additionally, elucidating the underlying mechanisms by which FUC interacts with gut epithelial cells and the gut microbiota will provide deeper insights into its modes of action. By addressing these factors, researchers can better harness the potential of FUC as a natural agent for mitigating intestinal damage and improving gut health.

Author Contributions

Conceptualization, T.W.; data curation, D.Z.; funding acquisition, T.W. and Q.Z.; investigation, Q.Z., M.W. and Z.L.; methodology, Q.Z. and M.W.; project administration, Q.Z.; supervision, T.W.; writing—original draft, Q.Z. and M.W.; writing—review and editing, T.W. and Y.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research was jointly funded by the Hubei Provincial Department of Education Innovative Team Project (T2023010), the National Natural Science Foundation of China (32302781), and the Natural Science Foundation of Hubei Province (2024AFB942).

Institutional Review Board Statement

The animal study protocol was approved by the Animal Care and Use Committee at Wuhan Polytechnic University (protocol code: WPU202305004; approved on 28 April 2023).

Informed Consent Statement

Not applicable.

Data Availability Statement

All data generated or analyzed during this study are included in this published article. The data of the current study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

  1. Chen, Y.; Cui, W.; Li, X.; Yang, H. Interaction Between Commensal Bacteria, Immune Response and the Intestinal Barrier in Inflammatory Bowel Disease. Front. Immunol. 2021, 12, 761981. [Google Scholar] [CrossRef]
  2. Jung, K.; Saif, L.J.; Wang, Q. Porcine epidemic diarrhea virus (PEDV): An update on etiology, transmission, pathogenesis, and prevention and control. Virus Res. 2020, 286, 198045. [Google Scholar] [CrossRef] [PubMed]
  3. Lin, F.; Zhang, H.; Li, L.; Yang, Y.; Zou, X.; Chen, J.; Tang, X. PEDV: Insights and Advances into Types, Function, Structure, and Receptor Recognition. Viruses 2022, 14, 1744. [Google Scholar] [CrossRef] [PubMed]
  4. Du, J.; Luo, J.; Yu, J.; Mao, X.; Luo, Y.; Zheng, P.; He, J.; Yu, B.; Chen, D. Manipulation of Intestinal Antiviral Innate Immunity and Immune Evasion Strategies of Porcine Epidemic Diarrhea Virus. Biomed. Res. Int. 2019, 2019, 1862531. [Google Scholar] [CrossRef]
  5. Ajayi, T.; Dara, R.; Misener, M.; Pasma, T.; Moser, L.; Poljak, Z. Herd-level prevalence and incidence of porcine epidemic diarrhoea virus (PEDV) and porcine deltacoronavirus (PDCoV) in swine herds in Ontario, Canada. Transbound. Emerg. Dis. 2018, 2018, 12858. [Google Scholar] [CrossRef]
  6. Hsueh, F.C.; Lin, C.N.; Chiou, H.Y.; Chia, M.Y.; Chiou, M.T.; Haga, T.; Kao, C.F.; Chang, Y.C.; Chang, C.Y.; Jeng, C.R.; et al. Updated phylogenetic analysis of the spike gene and identification of a novel recombinant porcine epidemic diarrhoea virus strain in Taiwan. Transbound. Emerg. Dis. 2020, 2020, 13365. [Google Scholar] [CrossRef]
  7. Mohammed, A.S.A.; Naveed, M.; Jost, N. Polysaccharides; Classification, Chemical Properties, and Future Perspective Applications in Fields of Pharmacology and Biological Medicine (A Review of Current Applications and Upcoming Potentialities). J. Polym. Environ. 2021, 29, 2359–2371. [Google Scholar] [CrossRef]
  8. Zayed, A.; Ulber, R. Fucoidan production: Approval key challenges and opportunities. Carbohydr. Polym. 2019, 211, 289–297. [Google Scholar] [CrossRef]
  9. Rasin, A.B.; Silchenko, A.S.; Kusaykin, M.I.; Malyarenko, O.S.; Zueva, A.O.; Kalinovsky, A.I.; Airong, J.; Surits, V.V.; Ermakova, S.P. Enzymatic transformation and anti-tumor activity of Sargassum horneri fucoidan. Carbohydr. Polym. 2020, 246, 116635. [Google Scholar] [CrossRef]
  10. Luthuli, S.; Wu, S.; Cheng, Y.; Zheng, X.; Wu, M.; Tong, H. Therapeutic Effects of Fucoidan: A Review on Recent Studies. Mar. Drugs 2019, 17, 487. [Google Scholar] [CrossRef]
  11. Pradhan, B.; Nayak, R.; Patra, S.; Bhuyan, P.P.; Behera, P.K.; Mandal, A.K.; Behera, C.; Ki, J.S.; Adhikary, S.P.; MubarakAli, D.; et al. A state-of-the-art review on fucoidan as an antiviral agent to combat viral infections. Carbohydr. Polym. 2022, 291, 119551. [Google Scholar] [CrossRef] [PubMed]
  12. Yang, W.; Chen, J.; Guo, G.; Wang, S.; Peng, S.; Gao, Z.; Zhao, Z.; Lan, R.; Yin, F. The Effects of Fucoidan Dietary Supplementation on Growth Performance, Serum Antioxidant Capacity, Immune Function Indices and Intestinal Morphology in Weaned Kids. Animals 2022, 12, 574. [Google Scholar] [CrossRef] [PubMed]
  13. Lim, J.M.; Yoo, H.J.; Lee, K.W. High Molecular Weight Fucoidan Restores Intestinal Integrity by Regulating Inflammation and Tight Junction Loss Induced by Methylglyoxal-Derived Hydroimidazolone-1. Mar. Drugs 2022, 20, 580. [Google Scholar] [CrossRef] [PubMed]
  14. Guo, X.; Chen, J.; Yang, J.; He, Q.; Luo, B.; Lu, Y.; Zou, T.; Wang, Z.; You, J. Seaweed polysaccharide mitigates intestinal barrier dysfunction induced by enterotoxigenic Escherichia coli through NF-κB pathway suppression in porcine intestinal epithelial cells. J. Anim. Physiol. Anim. Nutr. 2021, 105, 1063–1074. [Google Scholar] [CrossRef]
  15. Wei, Q.; Fu, G.; Wang, K.; Yang, Q.; Zhao, J.; Wang, Y.; Ji, K.; Song, S. Advances in Research on Antiviral Activities of Sulfated Polysaccharides from Seaweeds. Pharmaceuticals 2022, 15, 581. [Google Scholar] [CrossRef]
  16. Sugimoto, A.; Koike, T.; Kuboki, Y.; Komaba, S.; Kosono, S.; Aswathy, M.; Anzai, I.; Watanabe, T.; Toshima, K.; Takahashi, D. Synthesis of Low-Molecular-Weight Fucoidan Analogue and Its Inhibitory Activities against Heparanase and SARS-CoV-2 Infection. Angew. Chem. Int. Ed. Engl. 2025, 64, e202411760. [Google Scholar] [CrossRef]
  17. Yim, S.K.; Kim, K.; Kim, I.H.; Chun, S.H.; Oh, T.H.; Kim, J.U.; Kim, J.W.; Jung, W.H.; Moon, H.S.; Ku, B.S.; et al. Inhibition of SARS-CoV-2 Virus Entry by the Crude Polysaccharides of Seaweeds and Abalone Viscera In Vitro. Mar. Drugs 2021, 19, 219. [Google Scholar] [CrossRef]
  18. Wang, W.; Wu, J.; Zhang, X.; Hao, C.; Zhao, X.; Jiao, G.; Shan, X.; Tai, W.; Yu, G. Inhibition of Influenza A Virus Infection by Fucoidan Targeting Viral Neuraminidase and Cellular EGFR Pathway. Sci. Rep. 2017, 7, 40760. [Google Scholar] [CrossRef]
  19. Zhang, Q.; Li, P.; Li, H.; Yi, D.; Guo, S.; Wang, L.; Zhao, D.; Wang, C.; Wu, T.; Hou, Y. Multifaceted Effects and Mechanisms of N-Acetylcysteine on Intestinal Injury in a Porcine Epidemic Diarrhea Virus-Infected Porcine Model. Mol. Nutr. Food Res. 2022, 66, e2200369. [Google Scholar] [CrossRef]
  20. Koetzner, L.; Grover, G.; Boulet, J.; Jacoby, H.I. Plant-derived polysaccharide supplements inhibit dextran sulfate sodium-induced colitis in the rat. Dig. Dis. Sci. 2010, 55, 1278–1285. [Google Scholar] [CrossRef]
  21. Iraha, A.; Chinen, H.; Hokama, A.; Yonashiro, T.; Kinjo, T.; Kishimoto, K.; Nakamoto, M.; Hirata, T.; Kinjo, N.; Higa, F.; et al. Fucoidan enhances intestinal barrier function by upregulating the expression of claudin-1. World J. Gastroenterol. 2013, 19, 5500–5507. [Google Scholar] [CrossRef] [PubMed]
  22. Lean, Q.Y.; Eri, R.D.; Fitton, J.H.; Patel, R.P.; Gueven, N. Fucoidan Extracts Ameliorate Acute Colitis. PLoS ONE 2015, 10, e0128453. [Google Scholar] [CrossRef]
  23. Yu, J.; Liu, G.; Zhang, J.; Zhang, C.; Fan, N.; Xu, Y.; Guo, J.; Yuan, J. Correlation among serum biochemical indices and slaughter traits, texture characteristics and water-holding capacity of Tan sheep. Ital. J. Anim. Sci. 2021, 20, 1781–1790. [Google Scholar] [CrossRef]
  24. Wang, J.; Su, Z.; Feng, Y.; Xi, R.; Liu, J.; Wang, P. Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: A cross-sectional study in the Pearl River Delta region of southern China. BMC Gastroenterol. 2021, 21, 482. [Google Scholar] [CrossRef]
  25. Bassendine, M.F.; Sheridan, D.A.; Bridge, S.H.; Felmlee, D.J.; Neely, R.D. Lipids and HCV. Semin. Immunopathol. 2013, 35, 87–100. [Google Scholar] [CrossRef]
  26. Begue, F.; Tanaka, S.; Mouktadi, Z.; Rondeau, P.; Veeren, B.; Diotel, N.; Tran-Dinh, A.; Robert, T.; Vélia, E.; Mavingui, P.; et al. Altered high-density lipoprotein composition and functions during severe COVID-19. Sci. Rep. 2021, 11, 2291. [Google Scholar] [CrossRef]
  27. Koutroumpakis, E.; Ramos-Rivers, C.; Regueiro, M.; Hashash, J.G.; Barrie, A.; Swoger, J.; Baidoo, L.; Schwartz, M.; Dunn, M.A.; Koutroubakis, I.E.; et al. Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease. Dig. Dis. Sci. 2016, 6, 865–871. [Google Scholar] [CrossRef]
  28. Kazory, A. Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am. J. Cardiol. 2010, 106, 694–700. [Google Scholar] [CrossRef]
  29. Shen, Y.; Wu, S.D.; Chen, Y.; Li, X.Y.; Zhu, Q.; Nakayama, K.; Zhang, W.Q.; Weng, C.Z.; Zhang, J.; Wang, H.K.; et al. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response. Gut Microbes 2023, 15, 2155018. [Google Scholar] [CrossRef]
  30. Shiau, J.P.; Chuang, Y.T.; Cheng, Y.B.; Tang, J.Y.; Hou, M.F.; Yen, C.Y.; Chang, H.W. Impacts of Oxidative Stress and PI3K/AKT/mTOR on Metabolism and the Future Direction of Investigating Fucoidan-Modulated Metabolism. Antioxidants 2022, 11, 911. [Google Scholar] [CrossRef]
  31. Homer, B.; Barekatain, R.; Petrovski, K.R.; Plush, K.J.; Dwan, C.; D’Souza, D.N.; Verma, P.J.; Kirkwood, R.N.; Tucker, B.S. Preweaning Purified Fucoidan Drench: Effects on Growth, Immune Response, and Intestinal Morphology in Weaned Piglets. Animals 2024, 14, 1472. [Google Scholar] [CrossRef] [PubMed]
  32. Duarte, M.E.; Cardoso, M.A.; Noseda, M.D.; Cerezo, A.S. Structural studies on fucoidans from the brown seaweed Sargassum stenophyllum. Carbohydr. Res. 2001, 333, 281–293. [Google Scholar] [CrossRef] [PubMed]
  33. Liu, M.; Liu, Y.; Cao, M.J.; Liu, G.M.; Chen, Q.; Sun, L.; Chen, H. Antibacterial activity and mechanisms of depolymerized fucoidans isolated from Laminaria japonica. Carbohydr. Polym. 2017, 172, 294–305. [Google Scholar] [CrossRef] [PubMed]
  34. Yuguchi, Y.; Tran, V.T.T.; Bui, L.M.; Takebe, S.; Suzuki, S.; Nakajima, N.; Kitamura, S.; Thanh, T.T.T. Primary structure, conformation in aqueous solution, and intestinal immunomodulating activity of fucoidan from two brown seaweed species Sargassum crassifolium and Padina australis. Carbohydr. Polym. 2016, 147, 69–78. [Google Scholar] [CrossRef]
  35. Ryu, M.J.; Chung, H.S. Fucoidan reduces oxidative stress by regulating the gene expression of HO-1 and SOD-1 through the Nrf2/ERK signaling pathway in HaCaT cells. Mol. Med. Rep. 2016, 14, 3255–3260. [Google Scholar] [CrossRef]
  36. Tian, S.; Jiang, X.; Tang, Y.; Han, T. Laminaria japonica fucoidan ameliorates cyclophosphamide-induced liver and kidney injury possibly by regulating Nrf2/HO-1 and TLR4/NF-κB signaling pathways. J. Sci. Food Agric. 2022, 102, 2604–2612. [Google Scholar] [CrossRef]
  37. Raftery, N.; Stevenson, N.J. Advances in anti-viral immune defence: Revealing the importance of the IFN JAK/STAT pathway. Cell. Mol. Life Sci. 2017, 74, 2525–2535. [Google Scholar] [CrossRef]
  38. Hsueh, F.C.; Chang, Y.C.; Kao, C.F.; Hsu, C.W.; Chang, H.W. Intramuscular Immunization with Chemokine-Adjuvanted Inactive Porcine Epidemic Diarrhea Virus Induces Substantial Protection in Pigs. Vaccines 2020, 8, 102. [Google Scholar] [CrossRef]
  39. Hsu, C.W.; Chang, M.H.; Chang, H.W.; Wu, T.Y.; Chang, Y.C. Parenterally Administered Porcine Epidemic Diarrhea Virus-Like Particle-Based Vaccine Formulated with CCL25/28 Chemokines Induces Systemic and Mucosal Immune Protectivity in Pigs. Viruses 2020, 12, 1122. [Google Scholar] [CrossRef]
  40. Bohmwald, K.; Gálvez, N.M.S.; Canedo-Marroquín, G.; Pizarro-Ortega, M.S.; Andrade-Parra, C.; Gómez-Santander, F.; Kalergis, A.M. Contribution of Cytokines to Tissue Damage During Human Respiratory Syncytial Virus Infection. Front. Immunol. 2019, 10, 452. [Google Scholar] [CrossRef]
  41. Sekrecka, A.; Kluzek, K.; Sekrecki, M.; Boroujeni, M.E.; Hassani, S.; Yamauchi, S.; Sada, K.; Wesoly, J.; Bluyssen, H.A.R. Time-dependent recruitment of GAF, ISGF3 and IRF1 complexes shapes IFNα and IFNγ-activated transcriptional responses and explains mechanistic and functional overlap. Cell. Mol. Life Sci. 2023, 80, 187. [Google Scholar] [CrossRef] [PubMed]
  42. Perng, Y.C.; Lenschow, D.J. ISG15 in antiviral immunity and beyond. Nat. Rev. Microbiol. 2018, 16, 423–439. [Google Scholar] [CrossRef] [PubMed]
  43. Sarkar, L.; Liu, G.; Gack, M.U. ISG15: Its roles in SARS-CoV-2 and other viral infections. Trends Microbiol. 2023, 31, 1262–1275. [Google Scholar] [CrossRef] [PubMed]
  44. Zhang, W.; Hwang, J.; Yadav, D.; An, E.K.; Kwak, M.; Lee, P.C.; Jin, J.O. Enhancement of Immune Checkpoint Inhibitor-Mediated Anti-Cancer Immunity by Intranasal Treatment of Ecklonia cava Fucoidan against Metastatic Lung Cancer. Int. J. Mol. Sci. 2021, 22, 9125. [Google Scholar] [CrossRef]
  45. Pan, W.; Borovac, J.; Spicer, Z.; Hoenderop, J.G.; Bindels, R.J.; Shull, G.E.; Doschak, M.R.; Cordat, E.; Alexander, R.T. The epithelial sodium/proton exchanger, NHE3, is necessary for renal and intestinal calcium (re)absorption. Am. J. Physiol.-Renal Physiol. 2012, 302, F943–F956. [Google Scholar] [CrossRef]
  46. Login, F.H.; Nejsum, L.N. Aquaporin water channels: Roles beyond renal water handling. Nat. Rev. Nephrol. 2023, 19, 604–618. [Google Scholar] [CrossRef]
  47. Wang, J.X.; Yu, S.J.; Huang, G.; Yu, Y.B.; Li, Y.Q. Apolipoprotein A-I: Potential Protection Against Intestinal Injury Induced by Dietary Lipid. J. Inflamm. Res. 2024, 17, 5711–5721. [Google Scholar] [CrossRef]
  48. Wu, Q.; Wu, S.; Cheng, Y.; Zhang, Z.; Mao, G.; Li, S.; Yang, Y.; Zhang, X.; Wu, M.; Tong, H. Sargassum fusiforme fucoidan modifies gut microbiota and intestinal metabolites during alleviation of hyperglycemia in type 2 diabetic mice. Food Funct. 2021, 12, 3572–3585. [Google Scholar] [CrossRef]
  49. Morris, S.M., Jr. Arginine Metabolism Revisited. J. Nutr. 2016, 146, 2579S–2586S. [Google Scholar] [CrossRef]
  50. Lisi, F.; Zelikin, A.N.; Chandrawati, R. Nitric Oxide to Fight Viral Infections. Adv. Sci. 2021, 8, 2003895. [Google Scholar] [CrossRef]
  51. Liu, T.; Wang, Z.; Chen, X.; You, H.; Xue, J.; Cai, D.; Zheng, Y.; Xu, Y.; Luo, D. Low Molecular-Weight Fucoidan Protects Against Hindlimb Ischemic Injury in Type 2 Diabetic Mice Through Enhancing Endothelial Nitric Oxide Synthase Phosphorylation. J. Diabetes 2018, 10, 820–834. [Google Scholar] [CrossRef]
Figure 1. Histopathological structures of piglets’ duodenum, jejunum, ileum, and colon in the control, FUC, PEDV, and FUC+PEDV groups.
Figure 1. Histopathological structures of piglets’ duodenum, jejunum, ileum, and colon in the control, FUC, PEDV, and FUC+PEDV groups.
Animals 15 01001 g001
Figure 2. Transcriptomic analysis of PEDV-infected piglets treated with FUC in jejunum. (A) Overview of differentially expressed genes (DEGs; fold change > 1.5; q value < 0.05) in the jejunum. (B) Venn diagram showing overlapping DEGs between groups. (C,D) Biological process enrichment analysis of DEGs between different groups. (E,F) KEGG analysis of DEGs between different groups.
Figure 2. Transcriptomic analysis of PEDV-infected piglets treated with FUC in jejunum. (A) Overview of differentially expressed genes (DEGs; fold change > 1.5; q value < 0.05) in the jejunum. (B) Venn diagram showing overlapping DEGs between groups. (C,D) Biological process enrichment analysis of DEGs between different groups. (E,F) KEGG analysis of DEGs between different groups.
Animals 15 01001 g002
Figure 3. The mRNA expression of genes related to immune responses in the jejunum of piglets. MX1: Myxovirus Resistant 1; OASL: 2′-5′-Oligoadenylate Synthetase Like; ISG15: Interferon-Stimulated Gene 15; IFN-β: Interferon β; IL-1β: Interleukin-1β; CXCL2: Chemokine Ligand 2; S100A2: S100 Calcium-Binding Protein A2; IL-8: Interleukin-8. Values are means and pooled SEMs; n = 7. a,b,c Within a row, means with different superscripts differ; p < 0.05.
Figure 3. The mRNA expression of genes related to immune responses in the jejunum of piglets. MX1: Myxovirus Resistant 1; OASL: 2′-5′-Oligoadenylate Synthetase Like; ISG15: Interferon-Stimulated Gene 15; IFN-β: Interferon β; IL-1β: Interleukin-1β; CXCL2: Chemokine Ligand 2; S100A2: S100 Calcium-Binding Protein A2; IL-8: Interleukin-8. Values are means and pooled SEMs; n = 7. a,b,c Within a row, means with different superscripts differ; p < 0.05.
Animals 15 01001 g003
Figure 4. The mRNA expression of genes related to transport and arginine metabolisms in the jejunum of piglets. AQP3: Aquaporin 3; AQP10: Aquaporin 10; NHE2: Na+/H+ Exchanger 2; NHE3: Na+/H+ Exchanger 3; TRPV6: Transient Receptor Potential Cation Channel Subfamily V Member 6; KCNJ13: Potassium Inwardly Rectifying Channel Subfamily J Member 13; APOA1: Apolipoprotein A1; APOA4: Apolipoprotein A4; APOB: Apolipoprotein B; APOC3: ApolipoproteinC3; ARG1: Arginase 1; ASS1: Argininosuccinate Synthase 1. Values are means and pooled SEMs; n = 7. a,b,c,d Within a row, means with different superscripts differ; p < 0.05.
Figure 4. The mRNA expression of genes related to transport and arginine metabolisms in the jejunum of piglets. AQP3: Aquaporin 3; AQP10: Aquaporin 10; NHE2: Na+/H+ Exchanger 2; NHE3: Na+/H+ Exchanger 3; TRPV6: Transient Receptor Potential Cation Channel Subfamily V Member 6; KCNJ13: Potassium Inwardly Rectifying Channel Subfamily J Member 13; APOA1: Apolipoprotein A1; APOA4: Apolipoprotein A4; APOB: Apolipoprotein B; APOC3: ApolipoproteinC3; ARG1: Arginase 1; ASS1: Argininosuccinate Synthase 1. Values are means and pooled SEMs; n = 7. a,b,c,d Within a row, means with different superscripts differ; p < 0.05.
Animals 15 01001 g004
Table 1. Primer sequences used for qPCR analysis.
Table 1. Primer sequences used for qPCR analysis.
GeneForward (5′-3′)Reverse (5′-3′)Size (bp) References
RPL19AACTCCCGTCAGCAGATCCAGTACCCTTCCGCTTACCG147Present study
PEDV-MTCCCGTTGATGAGGTGATAGGATGCTGAAAGCGAAAA231Present study
PEDV-NTTGGTGGTAATGTGGCTGTTCTGGTTTCACGCTTGTTCTTCTT180Present study
PEDV-SCTCTCTGGTACAGGCAGCACGCTCACGTAGAGTCAAGGCA131Present study
IFN-βAGCAGATCTTCGGCATTCTCGTCATCCATCTGCCCATCAA101[19]
MX1AGTGCGGCTGTTTACCAAGTTCACAAACCCTGGCAACTC150[19]
OASLGGCACCCCTGTTTTCCTCTAGCACCGCTTTTGGATGG139[19]
ISG15AGCATGGTCCTGTTGATGGTGCAGAAATGGTCAGCTTGCACG164Present study
IL-1βCAACGTGCAGTCTATGGAGTGAGGTGCTGATGTACCAGTTG372Present study
CXCL2CGGAAGTCATAGCCACTCTCAACAGTAGCCAGTAAGTTTCCTCCATC143Present study
S100A2TAGGGCAGGTTTGGTTTCCTTGGGGACTGGACATCTTGGAT148Present study
IL-8TTCGATGCCAGTGCATAAATACTGTACAACCTTCTGCACCCA176Present study
AQP3AAGCTGTCCCAAGTAAAGCACAAGCCCTACTTCCTGTTTCACCAC251Present study
AQP10GGGCGTTATACTAGCCATCTACCCAACTGCACCAAGGAGTAA134Present study
NHE2CAGCGACTCAGACCCAGACACCACCTCGTTCTTCCATTCC128Present study
NHE3AAGTACGTGAAGGCCAACATCTCTTCTCCTTGACCTTGTTCTCGTC341Present study
TRPV6AGGAGCTGGTGAGCCTCAAGTGGGGTCAGTTTGGTTGTTGG146Present study
KCNJ13ATGGATGTGTCGCTGGTCTTTCACAACTGCTTGCCTTTACGAG141Present study
APOA1CCTTGGCTGTGCTCTTCCTCACGGTGGCAAAATCCTTCAC100Present study
APOA4ACCCAGCAGCTCAACACTCTCGAGTCCTTGGTCAGGCGTTC122Present study
APOBGGGATGATGGCACAGGTTACATGACGTGGACTTGGTGCTTT123Present study
APOC3CTAACCAGCGTGAAGGAGTCCAGAAGTCGGTGAACTTGCC116Present study
ARG1GGCTGGTCTGCTTGAGAAACATCGCCATACTGTGGTCTCC216Present study
ASS1CCCTCACTTTGCCCATCTCTCCCTACCCTTCCGTTTGCT163Present study
Table 2. Effects of FUC supplementation on growth performance after PEDV infection.
Table 2. Effects of FUC supplementation on growth performance after PEDV infection.
Items−PEDV+PEDVSEMp Vaule
−FUC+FUC−FUC+FUCPEDVFUCPEDV × FUC
ADG (Kg/d)0.0870.0930.0610.0520.007 0.030.9010.589
Diarrhea score 0.0000.0140.0860.1430.0020.0040.3040.535
PEDV, porcine epidemic diarrhea virus; FUC, fucoidan; ADG, average daily gain; SEM, standard error of the mean.
Table 3. Effects of FUC supplementation on the relative mRNA expression levels of PEDV in the small intestine of piglets infected with PEDV.
Table 3. Effects of FUC supplementation on the relative mRNA expression levels of PEDV in the small intestine of piglets infected with PEDV.
ItemsPEDVFUC+PEDVSEMp Value
Jejunum
PEDV-M1.000 b0.8090.0700.182
PEDV-N1.000 b2.696 a0.2640.000
PEDV-S1.000 b3.381 a0.3770.001
Ileum
PEDV-M1.000 b1.558 a0.1080.004
PEDV-N1.000 b2.099 a0.1680.000
PEDV-S1.000 b2.012 a0.1760.003
Colon
PEDV-M1.000 b2.497 a0.2440.000
PEDV-N1.000 b1.971 a0.1730.001
PEDV-S1.000 b1.689 a0.1220.001
PEDV, porcine epidemic diarrhea virus; FUC, fucoidan; PEDV-M, the M gene of PEDV; PEDV-N, the N gene of PEDV; PEDV-S, the S gene of PEDV; SEM, standard error of the mean. a,b Within a row, means with different superscripts differ; p < 0.05.
Table 4. The effects of FUC supplementation on plasma biochemicals in PEDV-infected piglets.
Table 4. The effects of FUC supplementation on plasma biochemicals in PEDV-infected piglets.
Iterms−PEDV+PEDVSEMp Value
−FUC+FUC−FUC+FUCPEDVFUCPEDV × FUC
TB (μmol/L)3.564 a3.781 a4.320 a1.813 b0.2670.1070.0040.001
TP (g/L)47.55747.25747.31452.4001.8470.1050.1130.076
ALB (g/L)28.22928.71428.91429.8141.1370.4570.5630.862
ALT (U/L)41.95745.20049.47150.1432.4250.1100.6060.735
ALP (U/L)375.602371.166347.514320.45017.6680.1520.5600.675
TC (mmol/L)3.2642.6972.4662.4710.1300.0020.0700.065
TG (mmol/L)0.5590.5340.6010.5930.0280.2580.7060.855
Glu (mmol/L)5.4265.6915.2015.4070.2380.4270.4610.925
CREA (μmol/L)73.07176.81470.90073.4143.4590.5900.5450.905
UREA (mmol/L)3.3334.2748.1398.7260.567<0.0010.2500.787
LDL-C (mmol/L)1.2641.0401.0061.0440.0540.1070.2340.097
HDL-C (mmol/L)1.4341.1641.0070.8500.063<0.0010.0030.388
LDH (U/L)421.000416.600414.971342.01417.0120.0300.0370.062
CK (U/L)217.473218.200224.543150.70013.0480.1600.0920.086
DB (μmol/L)1.461 b1.812 ab2.126 a0.480 c0.1420.031<0.001<0.001
Values are means and pooled SEMs; n = 7. a,b,c Within a row, means with different superscripts differ; p < 0.05. TB: total bilirubin; TP: total protein; ALB: albumin; ALT: alanine amino transferase; ALP: alkaline phosphatase; TC: total cholesterol; TG: triglyceride; GLU: glucose; CREA: creatinine; UREA: urea; HDL: high-density lipoprotein; LDL: low-density lipoprotein; LDH: lactate dehydrogenase; CK: creatine kinase; DB: direct bilirubin.
Table 5. The effects of FUC supplementation on DAO activity and d-xylose concentration in PEDV-infected piglets.
Table 5. The effects of FUC supplementation on DAO activity and d-xylose concentration in PEDV-infected piglets.
Items−PEDV+PEDVSEMp Value
−FUC+FUC−FUC+FUCPEDVFUCPEDV × FUC
DAO (U/L)16.56 c25.69 b29.15 a20.35 bc1.3870.1100.941<0.001
d-xylose (mmol/L)1.451.431.260.970.0540.0010.0700.106
Values are means and pooled SEMs; n = 7. a,b,c Within a row, means with different superscripts differ; p < 0.05. DAO: diamine oxidase.
Table 6. The effects of FUC supplementation on intestinal morphology in PEDV-infected piglets.
Table 6. The effects of FUC supplementation on intestinal morphology in PEDV-infected piglets.
Items−PEDV+PEDVSEMp Value
−FUC+FUC−FUC+FUCPEDVFUCPEDV × FUC
Duodenum
VH (μm)360.908 a355.606 ab249.086 d319.961 c10.6450.0000.0220.009
CD (μm)158.726154.45916157.01286147.834882.8170.4740.2520.672
VW (μm)110.78343111.1191794.985101.031551.9140.0000.2910.344
VA (μm2)40,924.675 a35,171.610 b23,976.708 d29,286.451 c1469.2290.0000.8990.004
VH/CD2.268 a2.317 a1.590 b2.171 a0.0650.0000.0000.001
Jejunum
VH (μm)371.570383.556215.493236.20915.4550.0000.1220.672
CD (μm)139.394139.591132.195126.4221.9610.0080.4340.403
VW (μm)97.91296.05991.07886.7271.1510.0000.0750.461
VA (μm2)34,976.14533,560.68020,664.13422,078.7581371.0490.0001.0000.251
VH/CD2.6702.7561.6281.8760.1010.0000.0410.307
Ileum
VH (μm)354.070 a353.723 a222.773 b326.387 a12.9000.0000.0040.004
CD (μm)128.167113.220126.508133.8833.5500.1790.5870.117
VW (μm)100.34697.89191.36399.4881.9040.3380.4600.174
VA (μm2)35,681.037 a31,296.865 ab20,144.727 d29,651.764 c1398.4540.0000.1800.001
VH/CD2.8133.1631.7862.4430.1250.0000.0050.361
Colon
CD (μm)232.782212.569271.902239.2495.3210.0000.0010.395
Values are means and pooled SEMs; n = 7. a,b,c,d Within a row, means with different superscripts differ; p < 0.05. VH: villus height; CD: crypt depth; VA: villus area; VW: villus width.
Table 7. The effects of FUC supplementation on the intestinal antioxidant capacity in PEDV-infected piglets.
Table 7. The effects of FUC supplementation on the intestinal antioxidant capacity in PEDV-infected piglets.
Items−PEDV−PEDVSEMp Value
−FUC+FUC−FUC+FUCPEDVFUCPEDV × FUC
H2O2 (mmol/L; mmol/mg protein)
plasma32.03629.73023.47518.9531.5750.0010.2010.673
duodenum14.03612.74814.01612.2630.4720.7930.1220.809
jejunum10.175 a9.879 a9.444 a6.867 b0.3600.0020.0150.047
ileum16.9 a13.021 b14.082 ab9.111 c0.6830.0040.0000.427
colon8.7227.7138.4377.0850.2280.2730.0080.677
T-SOD (U/mL; U/mg protein)
plasma84.55084.14379.20182.1890.6330.0020.2220.112
duodenum240.66 a220.99 ab212.56 b233.89 ab3.920.2890.9060.007
jejunum183.145 a143.881 ab141.3 b175.654 ab7.0220.6980.8500.008
ileum230.183223.912217.078244.6307.0160.7920.4640.248
colon258.561 a243.451 ab233.565 b252.174 ab4.0290.2970.8210.037
MDA (mmol/L; nmol/mg protein)
plasma1.7351.7252.1141.9390.0700.0360.4940.539
duodenum1.0741.0891.4881.3010.0580.0050.4080.330
jejunum0.48 a0.344 b0.417 ab0.431 ab0.0180.7180.0680.028
ileum1.264 a0.936 b1.383 a0.424 c0.0820.0290.0000.001
colon0.492 b0.378 b0.548 ab0.710 a0.0370.0050.6980.036
GSH-PX (U/L; U/mg protein)
plasma276.408299.433275.274276.3273.9750.1120.1140.148
duodenum151.147 a112.024 b135.487 a151.521 a4.6610.1200.1310.001
jejunum83.68699.66396.985103.5813.1500.1610.0700.438
ileum179.803172.545129.562113.1917.0460.0000.2290.638
colon123.696117.602101.892119.1764.1120.2210.4940.159
MPO (U/mL; U/mg protein)
plasma44.95743.71442.35538.8471.4420.2120.4230.701
duodenum0.154 c0.172 b0.189 a0.153 c0.0180.0540.0270.000
jejunum0.076 b0.088 ab0.101 a0.073 b0.0040.4380.2060.005
ileum0.1940.1880.2270.1850.0050.1110.0120.058
colon0.1160.0940.1060.0990.0030.6780.0290.237
Values are means and pooled SEMs; n = 7. a,b,c Within a row, means with different superscripts differ; p < 0.05. H2O2: hydrogen peroxide; T-SOD: total superoxide and dismutase; MDA: malondialdehyde; GSH-Px: glutathione peroxidase; MPO: myeloperoxidase.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zhang, Q.; Wang, M.; Li, Z.; Zhao, D.; Hou, Y.; Wu, T. Fucoidan Alleviates Porcine Epidemic Diarrhea Virus-Induced Intestinal Damage in Piglets by Enhancing Antioxidant Capacity and Modulating Arginine Metabolism. Animals 2025, 15, 1001. https://doi.org/10.3390/ani15071001

AMA Style

Zhang Q, Wang M, Li Z, Zhao D, Hou Y, Wu T. Fucoidan Alleviates Porcine Epidemic Diarrhea Virus-Induced Intestinal Damage in Piglets by Enhancing Antioxidant Capacity and Modulating Arginine Metabolism. Animals. 2025; 15(7):1001. https://doi.org/10.3390/ani15071001

Chicago/Turabian Style

Zhang, Qian, Maojing Wang, Zhonghua Li, Di Zhao, Yongqing Hou, and Tao Wu. 2025. "Fucoidan Alleviates Porcine Epidemic Diarrhea Virus-Induced Intestinal Damage in Piglets by Enhancing Antioxidant Capacity and Modulating Arginine Metabolism" Animals 15, no. 7: 1001. https://doi.org/10.3390/ani15071001

APA Style

Zhang, Q., Wang, M., Li, Z., Zhao, D., Hou, Y., & Wu, T. (2025). Fucoidan Alleviates Porcine Epidemic Diarrhea Virus-Induced Intestinal Damage in Piglets by Enhancing Antioxidant Capacity and Modulating Arginine Metabolism. Animals, 15(7), 1001. https://doi.org/10.3390/ani15071001

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop